| Autor: |
Nur Ferhatlar, Esma Demirhan, Selcen Kanyılmaz, Sevgi Atar, Ömer Kuru |
| Jazyk: |
English<br />Turkish |
| Rok vydání: |
2023 |
| Předmět: |
|
| Zdroj: |
Türk Osteoporoz Dergisi, Vol 29, Iss 2, Pp 84-88 (2023) |
| Druh dokumentu: |
article |
| ISSN: |
2147-2653 |
| DOI: |
10.4274/tod.galenos.2022.90277 |
| Popis: |
Objective:Our aim was to compare the bone mineral density (BMD) levels in axial spondyloarthropathy (AxSpA) patients treated with tumor necrosis factor-α (TNFα) agents and interleukin-17 (IL-17) blockers.Materials and Methods:This retrospective study was approved by the local ethics committee (07/01/2020, 7). We evaluated the medical records of AxSpA patients treated with either anti-TNFα or IL-17 blocker. Sixty-six patients with two consecutive dual energy X-ray absorptionmetry measurements (baseline and year one) were included. Twenty-seven patients were receiving anti-TNFα and 39 patients were receiving IL-17 blocker treatment. Outcome measures were compared between the IL-17 blocker and anti-TNFα agent treatment groups.Results:Sixty-two percent of the patients were male and 38% were female. The mean lumbar region (L1-L4) BMD value of the patients was 1.19±0.15 gr/cm2 and the mean femoral neck BMD value was 0.95±0.13 gr/cm2 at baseline (p>0.05). A statistically significant increase in BMD values in the lumbar region (L1-L4, L2-L4), femoral neck and femur total was detected at the end of one year observation in patients using both anti-TNF and IL-17 blockers (p |
| Databáze: |
Directory of Open Access Journals |
| Externí odkaz: |
|
